- |||||||||| 5-fluorouracil / Generic mfg.
CAN TUMOR RESPONSE TO INDUCTION CHEMOTHERAPY PREDICT TME-FREE SURVIVAL AFTER TOTAL NEOADJUVANT THERAPY FOR LOCALLY ADVANCED RECTAL CANCER? (207A - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6394;
Our data indicate that when an organ preservation strategy is pursued, the tumor response to induction chemotherapy predicts the probability of TME-free survival early in the treatment course. This benefit of induction chemotherapy should be considered when the chemotherapy sequence or treatment escalation and de-escalation, based on tumor response, is investigated in future research designed to maximize organ preservation.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
TREATMENT OF RECTAL CANCER BY TOTAL NEOADJUVANT THERAPY AND TRANSANAL LIMITED LOCAL EXCISION FOR COMPLETE RESPONDERS: PHASE II TRIAL RESULTS (207A - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6392;
All patients received 6 cycles of induction FOLFOX followed by concurrent Capecitabine/5FU infusion and external beam radiation...To date, 10/22 patients avoided TME and ultimate pelvic control was achieved in all patients. CONCLUSION Organ preservation via LLE for complete responders after TNT is not associated with frequent and severe morbidity and results in good local control.
- |||||||||| 5-fluorouracil / Generic mfg.
NEOADJUVANT CHEMOTHERAPY VERSUS UPFRONT SURGERY IN RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA: A NATIONAL CANCER DATABASE INTENTION-TO-TREAT ANALYSIS (207A - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6150;
The recent NORPACT-1 trial compared neoadjuvant FOLFIRINOX (4 cycles + surgery + 8 cycles) versus adjuvant FOLFIRINOX (surgery + 12 cycles) and reported worse median survival of 25.1 months in the NAC group versus 38.5 months with upfront surgery...The decision to proceed with upfront surgery versus NAC for resectable PDAC is complex and should be personalized for each patient. Results from this real-world cohort support upfront surgery, in line with the recently reported randomized trial.
- |||||||||| 5-fluorouracil / Generic mfg.
SBRT AFTER NEOADJUVANT CHEMOTHERAPY (NAC) FOR LOCALLY ADVANCED PANCREATIC CANCER (LAPC): PRELIMINARY INSTITUTIONAL RESULTS. (207B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6146;
Materials and Methods In our tertiary referral center, patients with LAPC undergo a complete course of NAC (mostly FOLFIRINOX), cross-sectional imaging reevaluation in 2 weeks and exploration for possible resection when the tumor looks resectable, en-block with the involved major vascular structure(s)...Seven patients are alive for a median of 15 months and 6 patients died at a median of 15 months. Conclusions Our initial experience shows that SBRT following NAC for LAPC is safe, is associated with a high rate of local control and may render resectable about one third of patients considered unresectable after NAC alone.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
USE OF DEEP LEARNING TO EVALUATE TUMOR MORPHOLOGICAL FEATURES FOR PREDICTION OF COLON CANCER RECURRENCE (152AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_362;
A deep learning algorithm (QuantCRC) applied to routine colon cancer sections enhances interpretive accuracy by identifying distinct morphological features driving patient prognosis within MMR groups. Our independently validated results can enable patient risk stratification for recurrence.
- |||||||||| Trial primary completion date: Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) - Mar 12, 2024
P1/2, N=120, Recruiting,
Possible variation in IS prognostic value by age and MMR status, and prediction of benefit from extended adjuvant therapy merit validation. Trial primary completion date: Jun 2024 --> Dec 2024
- |||||||||| lunresertib (RP-6306) / Repare Therap
Enrollment closed, Enrollment change, Combination therapy, Metastases: MINOTAUR: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (clinicaltrials.gov) - Mar 12, 2024
P1, N=36, Active, not recruiting,
Recruiting --> Active, not recruiting | N=30 --> 5 Recruiting --> Active, not recruiting | N=104 --> 36
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 12, 2024
P3, N=464, Active, not recruiting,
Recruiting --> Active, not recruiting | N=104 --> 36 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2024 | Trial primary completion date: Jun 2021 --> Jul 2023
- |||||||||| Synthesis of a daucane-type natural product with antiausterity activity against the PANC-1 pancreatic cancer cells (Virtual; Virtual Session (Virtual Only)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_7940;
Current standard-of-care first-line chemotherapeutic agents including FOLFIRINOX and gemcitabine/nab-paclitaxel regimens only offered limited increase in median survival rates, and development of new treatment strategies is necessary...Upon completion of the syntheses, mode-of-action studies of ferutinin will be conducted. Analogs of the target compound will be designed and synthesized, and structure-activity relationships (SARs) will be established to guide future development of antiausterity agents to treat human pancreatic cancer.
- |||||||||| Combination drug delivery using mesoporous silica nanoparticles for targeted therapy in pancreatic cancer | Poster Board #1219 (In-person; Poster Board #1219; Hall C (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_1437;
Current standards of care for PDAC involve the combination of two drugs (Gemcitabine+nab-paclitaxel) or more (FOLFIRINOX); however, combinations produce dramatic toxic effects on patients...In this study, we synthesized an MSN platform chemically loaded with cisplatin (cisPt) to internal pores and conjugated with gemcitabine (Gem) to the external surface of MSNs (Gem-cisPt-MSNs)...In addition, this synergistic effect is drug ratio-dependent. We envision that the use of nanoparticles will help to alleviate some of the main issues related to the treatment of PDAC; in particular, the drug resistance against current standard of care.
- |||||||||| Journal: Long-Term Suppression with First-Line Chemotherapy(FOLFIRI plus BV)for Peritoneal Metastasis (Pubmed Central) - Mar 11, 2024
A 72-year-old man underwent right hemicolectomy for transverse colon cancer(pT4aN1aM0, Stage ?B), after which he received adjuvant chemotherapy(capecitabine plus oxaliplatin[CAPOX])for 6 months...He underwent a tumorectomy and adjuvant chemotherapy(CAPOX plus bevacizumab[BV])performed for 6 months...A central venous(CV)port was implanted for access to the right internal jugular vein, and he received systemic chemotherapy(fluorouracil, Leucovorin, and irinotecan[FOLFIRI]plus BV)as an outpatient...He had surgery, but follow-up CT performed 8 years after the first surgery detected multiple liver metastasis. It was considered necessary to take infection control measures during long-term chemotherapy.
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2). (Pubmed Central) - Mar 8, 2024
This was an ad hoc analysis of a KSCC1301 randomized phase II trial in which patients with untreated resectable LARC were randomly assigned to receive S-1 and oxaliplatin or folinic acid, 5-fluorouracil, and oxaliplatin as NAC...NAC was associated with increased expression of ICMs and TILs. Rectal cancer could be susceptible to combined immunotherapy with chemotherapy.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Descriptive Landscape for Precision Medicines in Second-Line Biliary Tract Cancer: A Targeted Literature Review () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_747;
In 2L BTC, FOLFOX/FOLFIRI were the most frequently mentioned treatment options, while HER2, FGFR2 , KRAS/ MAPK, IDH1/IDH2 , BRAF , BRCA, and microsatellite instability were the most discussed actionable alterations. Ongoing clinical investigations may cause a shift in the treatment paradigm from chemotherapy to targeted therapies in the context of the efficacy, tolerability, and potential economic value of the latter.
- |||||||||| Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Real-World Treatment Patterns, Sequencing, and Unmet Need in Metastatic Colorectal Cancer (mCRC) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_664;
Real-world treatment patterns in mCRC are quite varied in later LOTs and characterized by the utilization of a wide variety of chemotherapy and targeted therapy. Also, minimal use of regorafenib or TAS-102 and substantial recycling of chemotherapies in relapsed/refractory setting was observed in later lines, pointing to a high level of unmet need in this population.
- |||||||||| methotrexate / Generic mfg.
Cough-headache as a Novel Presentation of Methotrexate Neurotoxicity (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3488;
Patients receiving high-dose or intrathecal MTX are also at high risk of spontaneous intracerebral hemorrhage which should first be ruled out. Following initial imaging, MTX neurotoxicity should be considered in the differential with appropriate imaging ordered to evaluate for its presence.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Immune Checkpoint Inhibitor-associated Kelch-like Protein-11 IgG Rhombencephalitis (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2605;
Tumor staining revealed KLHL11 immunoreactivity, supporting an ICI-associated paraneoplastic syndrome. It is critical to recognize and report novel nirAEs, in an effort to initiate early treatment and prevent progressive neurological disability.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. (Pubmed Central) - Mar 7, 2024
Osteoporosis and osteoporotic fractures were highly prevalent in patients with advanced pancreatic cancer. This study highlights the importance of screening for osteoporosis in such patients.
- |||||||||| Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen
Journal, Metastases: Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. (Pubmed Central) - Mar 7, 2024
Promising inhibitors such as sotorasib and adagrasib targeting KRASG12C mutations have demonstrated efficacy...Treatment with FOLFIRINOX and bevacizumab, and later FOLFIRI and bevacizumab, with surgeries and local interventions resulted in partial responses...This case highlights the remarkable outcome of a heavily treated KRAS G12C mutant mCRC patient. The combination of sotorasib and panitumumab, along with multidisciplinary approaches including surgery and local interventions, played an important role in our patient's survival.
- |||||||||| Trial completion date, Trial primary completion date: SHORT-FOX: Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer (clinicaltrials.gov) - Mar 7, 2024
P2, N=38, Active, not recruiting,
The combination of sotorasib and panitumumab, along with multidisciplinary approaches including surgery and local interventions, played an important role in our patient's survival. Trial completion date: May 2027 --> Jan 2026 | Trial primary completion date: May 2025 --> Jan 2024
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy (clinicaltrials.gov) - Mar 7, 2024
P1/2, N=20, Recruiting,
Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2025 Trial completion date: Jan 2025 --> Aug 2025 | Trial primary completion date: Jan 2023 --> Aug 2024 | Not yet recruiting --> Recruiting
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment open, Metastases: ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) - Mar 6, 2024
P2/3, N=150, Recruiting,
Further studies should evaluate these findings in more detail. Not yet recruiting --> Recruiting
- |||||||||| 5-fluorouracil / Generic mfg.
Immune surveillance of chemotherapy-induced mutant subclones in CRC (Section 2) - Mar 5, 2024 - Abstract #AACR2024AACR_8229;
We have previously reported that temozolomide (TMZ) is able to induce MMR defects and hypermutability leading to immunotherapy clinical benefit in the subset of CRCs characterized by inactivation of O6-methylguanine methyltransferase (MGMT)...For this reason, we investigated the impact of treatment with TMZ and cisplatin (CDDP), as well as other commonly used cytotoxic agents in CRC such as 5-fluorouracil, irinotecan and oxaliplatin, on the immunogenomic features of murine CRC cells...These results indicate that rational combinations of commonly used cytotoxic agents can be exploited to promote cancer cell subclonal and clonal hypermutability. This approach can be used to promote cancer immunogenicity with implications for the design of new chemo-immunotherapy strategies in CRC.
- |||||||||| ADU-S100 / Novartis
Role of major facilitative folate transporters SLC19A1 and SLC46A1 in cyclic dinucleotide transport and STING signaling (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_8068;
was seen in THP-1 and R1-11/Tet-on-RFC cells by ADU-S100 treatment at pH 7.2 (RFC pH optimum) in the presence of 25 nM leucovorin...In conclusion, RFC mediates ADU-S100 uptake and STING activation under physiologic conditions and this process is enhanced by concomitant expression of PCFT. Additional characterization of key molecular and biochemical determinants of CDN-based cancer therapeutics may lead to improved approaches for CDN therapy based on enhanced cellular uptake.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Targeting vulnerabilities of drug-tolerant persister cells in gastric cancer (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_8067;
We identified a significant downregulation of genes strictly correlated to the HR machinery, suggesting that the FOLFIRI-induced persister cells can temporarily enter in a "BRCAness" status that may be used for a synthetic lethality approach using PARP inhibitors. Targeting the drug tolerant persister state is an essential approach to diminish cancer cells when they are potentially in their most vulnerable state.
|
